Full Title
A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 AntibodyPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Saad Usmani’s office at 646-608-4165.
Protocol
25-304
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07266441